Abstracts tagged "T Cell"

Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Blake Warner¹, Billel Gasmi², David Kleiner³, Paola Perez Riveros⁴, Daniel Barber⁵, Shunsuke Sakai⁵ and Alan Baer⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, ²National Cancer Institute, Bethesda, MD, ³National Cancer Institute, Bethesda, ⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
Abstract Number: 0948 • ACR Convergence 2020
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Ricardo Grieshaber-Bouyer¹, Joshua Keegan², Peter Nigrovic³, James Lederer⁴ and Deepak Rao², ¹Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴BWH Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…
Abstract Number: 1443 • ACR Convergence 2020
High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN
Runci Wang¹, Karmela Kim Chan², Amy Cunningham-Bussel¹, Gregory Vitone³, Aidan Tirpack², Caroline Benson², Gregory Keras⁴, Anna Helena Jonsson⁵, Michael Brenner⁵, Laura Donlin⁶, Anne Bass⁷ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, ⁴Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Checkpoint inhibitors (CI) used to treat cancer frequently trigger immune-related adverse events, including inflammatory arthritis. CI-related arthritis (CIrA) occurs in ~5% of treated patients,…
Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt¹, Kevin Wei², Siobhan Case³, Margaret Chang¹, Ezra Cohen¹, Fatma Dedeoglu¹, Melissa Hazen¹, Jonathan Hausmann⁴, Olha Halyabar⁵, Erin Janssen⁵, Pui Lee⁶, Jeffrey Lo¹, Mindy Lo¹, Esra Meidan⁷, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel⁵, Talal Chatila¹, Peter Nigrovic⁸ and Lauren Henderson⁹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵Children's Hospital/Boston Medical Center, Boston, MA, ⁶1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁷Boston Children's Hospital, Somerville, MA, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁹Boston Children's Hospital, Watertown, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…
Abstract Number: 0972 • ACR Convergence 2020
Mapping Oligoclonally Expanded T Cells Within the Peripheral and Synovial Immune Landscape of Untreated ACPA+ Rheumatoid Arthritis Patients at the Single Cell Level
Pascale Wehr¹, Hendrik Nel¹, Chenhao Zhou², Ahmed Mehdi², Angelika Christ³, Helen Weedon⁴, Mihir Wechalekar⁵ and Ranjeny Thomas⁶, ¹University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³University of Queensland Institute for Molecular Bioscience, Brisbane, Australia, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵Flinders Medical Centre, Adelaide, South Australia, Australia, ⁶University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: Clonal T cell expansions – some large – have been identified in the peripheral blood (PB) and in synovial tissue (ST) of multiple joints…
Abstract Number: 1480 • ACR Convergence 2020
Abatacept for the Treatment of IgG4-Related Disease
Mark Matza¹, Cory Perugino¹, Liam Harvey², Zachary Wallace³, Hang Liu⁴, Shiv Pillai⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital, Cambridge, MA, ⁵Harvard Medical School, Cambridge, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: To assess the efficacy and safety of abatacept (ABA) for the treatment of IgG4-related disease (IgG4-RD). To date, there are no FDA-approved treatments available…
Abstract Number: 0472 • ACR Convergence 2020
ApoB:ApoA1 Ratio Could Predict Atherosclerotic Risk in Juvenile-SLE Patients Associated with Altered Interferon Signalling in CD8+ T-cells
George Robinson¹, Kirsty Waddington², Leda Coelewij², Junjie Peng², Meena Naja², Chris Wincup², Anna Radziszewska², Hannah Peckham², David Isenberg², Yiannis Ioannou², Ines Pineda Torra², Coziana Ciurtin² and Elizabeth Jury², ¹University College London, Hertford, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by immune-dysregulation, chronic inflammation, type-I interferon (IFN) signatures and increased cardiovascular disease (CVD) risk…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Adam Lefferts¹, Emilie Regner², Eric Norman³, David Claypool⁴, Hannah Schultz⁴, Danielle Sansone-Poe⁴ and Kristine Kuhn⁵, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of California San Francisco, San Francisco, CA, ³University of Colorado, Anschutz Medical Campus, Denver, ⁴University of Colorado, Anschutz Medical Campus, Aurora, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…
Abstract Number: 90 • 2019 ACR/ARP Annual Meeting
SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation
Matthew Dragovich¹ and Adam Mor ², ¹Columbia University, New York, NY, ²Columbia University School of Medicine, New York, NY
Background/Purpose: The signaling lymphocytic activation molecule (SLAM) family is encompassed by nine distinct receptors that are hematopoietic restricted. Among these, SLAMF6 is highly expressed in…
Abstract Number: 106 • 2019 ACR/ARP Annual Meeting
Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects
Achilleas Floudas¹, Douglas Veale ² and Ursula Fearon ³, ¹Trinity Biomedical Sciences Institu, DUBLIN, Ireland, ²EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ³Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland
Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…
Abstract Number: 124 • 2019 ACR/ARP Annual Meeting
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Paula Fortea-Gordo ², Laura Nuño ³, Alejandro Villalba ⁴, Maria-Jose Santos-Bornez ², Diana Peiteado ², Irene Monjo ¹ and Alejandro Balsa ⁵, ¹FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz, Madrid, Spain, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁴FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁵Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: Circulating CD4 T cells that express CXCR5 together with PD-1 and/or ICOS are considered as counterparts of bona fide Tfh cells and function as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].